GDP vaccine mega-warehouse (25,000 pallets) — India
Top-5 global vaccine manufacturer built a GDP + WHO PQ-compliant mega-warehouse serving domestic and UNICEF/GAVI export markets, including mRNA ULT storage.
Challenge
- Zero-excursion mandate across +2/+8, −20 and −70 °C zones in one envelope.
- 45 °C summer ambient + monsoon humidity load on envelope.
- WHO PQ, GDP, 21 CFR Part 11 and CDSCO compliance in one validation programme.
ColdMatch solution
- Triple-loop refrigeration: chilled water for +2/+8 °C, NH₃/CO₂ for −20 °C, cascade ULT for −70 °C.
- N+2 chiller redundancy, dual-utility (grid + diesel + BESS) with 72h autonomy.
- 21 CFR Part 11 monitoring (2,400 wireless loggers), calibrated mapping ×3 seasons.
- ColdMatch coordinated EPC + ULT OEM + validation partner + WHO PQ audit prep.
Project scope
- Civil: 42,000 m² envelope, 350 mm PIR, vapour barrier, sub-floor heating.
- Mechanical: 6 MW chilled water plant, 2.8 MW NH₃/CO₂, 12× ULT cascade cabinets (−70 °C).
- Electrical: 12 MVA connection, 3 MW diesel N+1, 4 MWh BESS, dual MV feed.
- Automation: BMS, EMS (ISO 50001), 21 CFR Part 11 monitoring, SCADA + ERP integration.
- Validation: URS/DQ/IQ/OQ/PQ, seasonal mapping, WHO PQ + CDSCO audit dossiers.
Key engineering metrics
- Cooling load (total)
- 8.8 MW
- Specific energy
- 34 kWh/m³·yr
- Availability (validated)
- 99.997%
- Mapping deviations (Y1)
- 0
- Backup autonomy
- 72 h
- Refrigerant charge
- R1234ze + NH₃ low-charge + R170 (ULT)
weighted across 3 zones
ROI & financial performance
- Capex
- US$ 78M
- Annual savings
- US$ 9.4M/yr (vs distributed legacy sites)
- Payback
- 8.3 yrs
- IRR
- 13.6% (15-yr)
- NPV
- US$ 24M @ 10% WACC
- Energy reduction
- −29% vs distributed baseline
- CO₂ reduction
- −3,100 t CO₂e/yr
“Zero excursions in year one across three temperature zones. The validation programme cleared WHO PQ on the first submission.”
How this project was delivered — planning to commissioning
Public-health programme delivery with independent qualification oversight. Total programme: 28 months, concept to national distribution.
- 1
Planning & feasibility
Months 1–6- National distribution modelling for campaign peaks and routine immunisation volumes.
- Ultra-low, frozen and +2/+8 °C zone sizing with holdover-time requirements.
- Validation master plan and URS issued before procurement.
Milestone: Programme scope, capacity and validation strategy approved.
- 2
Permitting & approvals
Months 6–12- Drug licensing authority approvals for storage and distribution.
- State pollution control, fire and building approvals secured.
- Import and cold-chain handling protocols agreed with the health ministry.
Milestone: Storage licence pathway and statutory approvals in place.
- 3
Procurement & build-out
Months 12–23- Redundant refrigeration plant, generators and UPS-backed monitoring installed.
- Ultra-low freezer farm and cold rooms constructed with segregated access control.
- Continuous monitoring platform deployed with calibrated, mapped sensors.
Milestone: Construction complete with all systems energised and backed up.
- 4
Testing & validation
Months 23–27- IQ / OQ / PQ across every storage zone including freezer farm units.
- Power-failure holdover and generator changeover testing under load.
- Excursion, recall and stock-integrity procedures rehearsed end to end.
Milestone: Qualification dossier complete with holdover performance evidenced.
- 5
Commissioning & handover
Months 27–28- Staff certification on GDP handling, alarm response and excursion management.
- Distribution network dry-run before live vaccine receipt.
- Calibration, service and audit calendar handed to the operator.
Milestone: Facility released for national vaccine distribution.
This project sits under the Build a Pharmaceutical Cold Chain objective. Start from the objective hub to scope capacity, permitting and budget before engaging suppliers.
Project brief → RFQ package → supplier outreach → outcome
Every ColdMatch project follows the same managed sequence. Nothing reaches a supplier before David has reviewed the brief and confirmed the project scope, budget and timeline.
1. Project brief
- Submitted via
- Pharma cold-chain RFQ — vaccine distribution
- Review
- Reviewed manually by David with GDP and ultra-low-temperature specialists
Clarified before outreach
- Volume split across +2/+8 °C, −20 °C and −70 °C storage.
- Continuity expectation during grid interruptions and monsoon conditions.
- Audit scope: national regulator plus international donor requirements.
Qualification checks
- Project value far above threshold, with programme funding confirmed.
- Named validation owner and quality lead on the buyer side.
- Distribution commitments fixed the go-live date.
2. RFQ package issued
Segmented RFQ per temperature regime, single commercial envelope
Documents in the pack
- URS per temperature zone, including −70 °C ULT redundancy strategy.
- Backup-power and hold-time requirements with defined failure scenarios.
- Mapping, monitoring and data-integrity specification.
- Serialization and inventory-system interface scope.
Mandatory supplier returns
- ULT redundancy design with failure-mode analysis.
- Guaranteed hold time per zone under total power loss.
- Validation plan with named resources and schedule.
- Spares availability and mean-time-to-repair commitments in-country.
3. Managed supplier outreach
- Approached
- 10 suppliers screened, including specialist ULT vendors
- Shortlisted
- 3 EPCs plus 2 ULT equipment vendors
- Round 1 — regulatory screen
Only suppliers with vaccine-grade references and in-country service progressed.
- Round 2 — technical tender
ULT redundancy and hold times reviewed against the URS with the quality team present.
- Round 3 — service commitment
In-country spares, response times and training negotiated into the contract.
Evaluation weighting
- Regulatory & validation capability
- 35%
- Redundancy and continuity
- 30%
- In-country service capability
- 20%
- Price (normalised scope)
- 15%
4. Commercial outcome
Multi-regime design with dedicated ULT redundancy and validated monitoring
Delivered results
- 25,000 pallet positions across +2/+8 °C, −20 °C and −70 °C.
- Validated monitoring accepted at first audit.
- Distribution commitments met on the original go-live date.
Use the pharma cold storage calculator, then submit a GDP brief for review.
Project records are anonymised at the buyer's request and presented as planning-grade benchmarks. Costs, timelines and performance figures are indicative and are not engineering designs or quotations.
Supplier and manufacturer listings are provided for research, transparency and discovery only. ColdMatch Group does not provide automatic buyer-supplier introductions. Every cold chain project request is reviewed manually by David / ColdMatch Group, and supplier introductions are made only after internal approval.